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Guidance on the choice of data sources for cost weights
in cost-effectiveness analyses in the literature is scarce
with few empirical examples of cost weights derived from
different approaches.
OBJECTIVES: This paper describes the large differences
that can be found in cost weights derived from different
data sources and analytic approaches. We highlight the
implications of the choice of costing data source and the
magnitude of error that could be introduced by assuming
data parity in direct comparisons of different studies.
Though our examples focus on HIV disease treatment,
the issues we explore are generic to cost estimation for all
conditions.
METHODS: We compared annual HIV disease treatment
cost weights from two data sets, the HIV Cost and 
Services Utilization Study (HCSUS) survey and South
Carolina Medicaid data. Cost weights for hospital and
nursing home stays and emergency room and physician
visits were included in the analyses.
RESULTS: The cost weights for Medicaid patients 
with AIDS were $15,033 in HCSUS and $10,281 in SC
Medicaid data. Within the HCSUS data set, cost weights
also varied greatly depending on whether the patient 
was covered by Medicaid ($15,033), Medicare ($8,487),
private ($4,200), or other public insurance ($19,347).
Further analysis of the HCSUS data found that the 
mean cost estimates for patients were larger when viral
load (VL) data was missing ($8,413) than when it was
included ($5,362). This difference was especially pro-
nounced at higher CD4 cell count ranges. For example,
the mean cost for patients with CD4 200–499 was $3,829
when VL was reported and $6,458 when it was missing,
a difference of 67%.
CONCLUSION: As this research illustrates, there may be
large differences in cost weights that are derived from dif-
ferent data sources and analytic approaches. Accordingly,
they should be given careful consideration when deter-
mining the external validity of economic studies.
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SATISFACTION WITH SMOKING CESSATION
TREATMENTS—A SYSTEMATIC REVIEW OF THE
DIMENSIONS
Holdford DA
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A major weakness of the literature on treatment satisfac-
tion is the lack of rigor in the development of satisfaction
measures. Part of this problem lies in the absence of an
accepted conceptual model for treatment satisfaction.
OBJECTIVES: This paper presents a conceptual mod-
el for treatment satisfaction and uses it to identify the
underlying dimensions associated with smoking cessation
treatments.
METHODS: A systematic literature review of databases
including MEDLINE, ABI-INFORM, Current Contents,
and IPA was conducted. Key words used for the litera-
ture search included drug, patient, smoking, physician,
pharmacist, placebo effect, and treatment satisfaction.
Articles included in the review focused on drug and
provider attributes shown in the literature to be signiﬁ-
cantly associated with overall perceptions of treatment
experiences. Treatment satisfaction attributes involving
high levels of patient-provider contact were emphasized
due to their relevance to smoking cessation treatments.
RESULTS: A conceptual model for treatment satisfaction,
based upon the review, was considered to consist of a
patient’s assessment of salient aspects of the process and
outcome of treatment experiences. Since treatment expe-
riences often contain the administration of both products
and services, the conceptual model was considered to
consist of both product and service attributes. Support
was found in the literature for this conceptualization since
evidence showed that both product and service attributes
have signiﬁcant impact on overall evaluations of treat-
ment experiences. Product-related attributes signiﬁcantly
impacting overall treatment satisfaction were categorized
under four of the product quality dimensions deﬁned by
Garvin (1984): Performance, Features, Aesthetics, and
Perceived Quality. Service-related attributes of treatment
were classiﬁed under the dimensions: Attitude, Respon-
siveness, Communication, Trust, Access, Motivation,
Expertise, and Tangibles.
CONCLUSION: The literature demonstrated support for
a conceptual model of treatment satisfaction with both
product- and service-related attributes. The inclusion of
service attributes is particularly important for treatments
consisting of high levels of patient-provider contact such
as with smoking cessation treatments. The dimensions in
this conceptual model can assist in the development of
treatment satisfaction measures.
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The Institute of Medicine Report on Patient Safety
requests a 50% reduction of adverse events. This
however, poses a challenge from a measurement perspec-
tive. Incidence estimates of adverse events have tradi-
tionally been based on medical case review, which is
exhaustive and costly. Furthermore, the reliability of this
method has been challenged. Recent studies have applied
information technology to screen for adverse drug events
(ADEs) in order to replace chart review.
OBJECTIVE: To explore the extent to which automated
health care data screens can be used to measure the inci-
dence of in-hospital ADEs.
METHODS: Systematic literature review. Keyword
search of MEDLINE (1980–2001) electronic database
and hand search. Included studies had to describe speciﬁc
screens that were applied to clinical or administrative
databases to detect in-hospital ADEs. They also had to
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formally evaluate the validity of the screens with regards
to their ability to correctly identify ADEs. Validity was
expressed as positive predictive value (PPV).
RESULTS: Ten studies published between 1992 and 2000
met the inclusion criteria. Three approaches used to
measure ADE incidence were identiﬁed. Two studies
screened for generic adverse outcomes (e.g., inpatient
deaths), the average PPVs were 1% and 17.4%. Five
studies exclusively screened for surrogate outcomes (anti-
dotes commonly used to treat ADEs, or critical lab values,
such as elevated creatinine or drug levels) to predict the
occurrence of an ADE, with PPVs of 9, 12, 13, 18 and
37%. Three studies tested screens that combined med-
ications and intermediate outcomes (PPVs 12.4, 45 and
53%).
CONCLUSIONS: Automated health care data screens
show promise as ADE incidence measure. Their current
validity, however, does not appear to be sufﬁcient for
cross-sectional comparisons or the evaluation of quality
improvement initiatives. Increasing sophistication of the
screens by including multiple variables that link process
components (e.g. medication) along with adverse out-
comes or surrogates (e.g. lab values, antidotes) appear to
increase screen validity.
MENTAL HEALTH (including Alzheimer’s Disease,
Dementia,Alcoholism, and Attention Deﬁcit
Disorder)—Clinical Outcomes Presentations
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USEFULNESS OF ELECTRONIC COMPLIANCE
DATA IN AN EFFECTIVENESS TRIAL
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OBJECTIVE: Effectiveness trials are designed to evaluate
patients in their natural setting with fewer constraints
than in efﬁcacy trials. The less-structured environ-
ment can result in a failed trial if participant activity is
unknown. We prepared for this possibility by including
electronic monitoring of medication dosing in a multi-
center trial.
METHODS: The trial was designed to assess the effec-
tiveness of naltrexone for the treatment of chronic 
alcoholism. Patients took either naltrexone or placebo
once daily, using MEMS caps (APREX, Union City, CA)
on their medication bottles to record the date and time
of each opening. We planned analyses by intention-
to-treat and covarying compliance as continuous and cat-
egorical variables (grouped as taking medication during
0–24%, 25–49%, 50–74%, >75% of weeks).
RESULTS: Primary endpoints showed no differences
between treatment groups at 3 months. Electronic moni-
toring revealed that patients took 72 + 31% of naltrex-
one and 70 + 31% of placebo doses (overall compliance
rates). Naltrexone was taken by 13%, 11%, 12%, and
65% of patients by category. Placebo was taken by 14%,
14%, 11%, and 61% of patients by category. Compliance
rates were not signiﬁcantly different overall or by cate-
gory between treatment groups. Planned secondary analy-
ses demonstrated that compliance was a predictor of
success (p = 0.03 for drinks/day), with no interaction for
treatment.
CONCLUSION: These data demonstrate the value of
electronic compliance measurement that provided data on
any period needed for analyses. Without these data, the
results of a complex and expensive study would have been
questioned. Critics could have charged that compliance
rates differed among treatment groups, or that inadequate
amounts of medication were taken to assess outcomes.
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The prognosis for patients with Alzheimer’s disease is
important information for physicians to be able to
provide patients and their relatives as an aid to making
appropriate arrangements before the severe stage is
reached.
OBJECTIVES: To provide prognosis aids for patients
with mild or moderate Alzheimer’s disease based on the
standardised Mini-Mental State Examination (SMMSE).
METHODS: Data from a Canadian cohort study of 206
patients with an initial SMMSE between 10 and 24 were
used to ﬁnd determinants of the three year probability of
reaching a highly dependent stage, deﬁned as SMMSE
<10. The regression equations were also used to derive a
reference failure-time curve. The predicted progression
was compared with that observed in a US study (N =
597).
RESULTS: Proportional hazards analyses showed that at
the mild stage (SMMSE 19 to 24) the presence of hallu-
cinations was associated with a more rapid decline,
whereas at the moderate stage (SMMSE 10 to 18) the
important predictors of decline were a lower baseline
SMMSE score and longer time since onset. Absence of
hallucinations in patients with an SMMSE above 18,
implied a 79% probability of remaining independent after
three years; presence of hallucinations reduced this to
52%, while a prior rate of decline of 2 points/year did so
even further to 43%. Less than half of patients whose
SMMSE was already below 19 and who had symptoms
for ﬁve years or longer remained independent after three
years. An initial score below 14 resulted in a probability
below 30%. The predictions based on the Canadian study
showed reasonable agreement with the progression
observed in the US study.
CONCLUSIONS: These equations permit estimation of
the expected progression of Alzheimer’s disease, and will
